Prognosis of Signet Ring Cell Gastric Carcinoma by Stage

Critical Staging Considerations

A minimum of 15 lymph nodes must be examined for adequate staging, with optimal evaluation requiring at least 25 nodes, as recommended by the National Comprehensive Cancer Network 1, 2, 3
The AJCC 8th edition TNM staging system should be used, with separate clinical (cTNM), pathologic (pTNM), and post-neoadjuvant (ypTNM) stage groupings, according to the National Comprehensive Cancer Network 1, 4, 5

Approximately 50% of gastric cancer patients present with advanced disease at diagnosis and have poor outcomes, as reported by the National Comprehensive Cancer Network 6
Performance status becomes the primary determinant of treatment approach, with best supportive care recommended for Karnofsky <60% or ECOG ≥3, as suggested by the National Comprehensive Cancer Network 5, 7
Systemic chemotherapy with fluoropyrimidine-platinum combinations is standard, though response rates remain poor in signet ring cell histology, according to Praxis Medical Insights 3, 8
HER2 testing should be performed, as trastuzumab plus chemotherapy improves outcomes in HER2-positive disease, as recommended by Praxis Medical Insights 3

Do not proceed without adequate lymph node evaluation (<15 nodes), as this leads to understaging and incorrect prognostic assessment, as warned by the National Comprehensive Cancer Network 1, 2, 3
Do not use pathologic staging criteria for clinical staging or post-neoadjuvant staging, as these have distinct prognostic implications, according to the National Comprehensive Cancer Network 1, 4, 5

The AJCC 8th edition provides distinct prognostic data for three staging scenarios based on datasets exceeding 25,000 patients, as reported by the National Comprehensive Cancer Network 1, 4, 5
Clinical staging (cTNM): Based on 4,091 patients from National Cancer Database and Shizuoka Cancer Center, validated in 4,374 Japanese patients, as described by the National Comprehensive Cancer Network 1, 4
Pathologic staging (pTNM): Based on >25,000 patients, provides most accurate prognostic information, according to the National Comprehensive Cancer Network 1, 4
Post-neoadjuvant staging (ypTNM): Based on 700 patients, presented in broad stage categories (I-IV), as reported by the National Comprehensive Cancer Network 1, 4